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 Encapsulation of therapeutic molecules within polymer particles is a well-established method for achieving
controlled release, yet challenges such as low loading, poor encapsulation efficiency, and loss of protein activity
limit clinical translation. Despite this, the paradigm for the use of polymer particles in drug delivery has re-
mained essentially unchanged for several decades. By taking advantage of the adsorption of protein therapeu-
tics to poly(lactic-co-glycolic acid) (PLGA) nanoparticles, we demonstrate controlled release without
encapsulation. In fact, we obtain identical, burst-free, extended-release profiles for three different protein ther-
apeutics with and without encapsulation in PLGA nanoparticles embedded within a hydrogel. Using both pos-
itively and negatively charged proteins, we show that short-range electrostatic interactions between the
proteins and the PLGA nanoparticles are the underlying mechanism for controlled release. Moreover, we dem-
onstrate tunable release by modifying nanoparticle concentration, nanoparticle size, or environmental pH. These
new insights obviate the need for encapsulation and offer promising, translatable strategies for a more effective
delivery of therapeutic biomolecules. ttp:/ o
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Controlled biomolecule release is a key strategy for reducing both the
systemic side effects associated with high drug concentrations and
the frequency of drug administration. One of the most widely stud-
ied methods for controlling biomolecule release is encapsulation
within a polymeric matrix, which slows diffusion. Poly(lactic-co-
glycolic acid) (PLGA) is widely used for encapsulation because of
its biocompatibility, biodegradability, wide range of degradation
rates, and long clinical history (1, 2).
PLGA is typically formulated into injectable, protein-containing mi-
croparticles or nanoparticles by double-emulsion solvent evaporation,
phase separation, or spray-drying techniques (3). All of these methods
involve organic solvents, high shear forces, and/or high temperatures that
result in protein denaturation and aggregation (4). In addition, PLGA
protein formulations often suffer from low encapsulation efficiency and
low protein loading (5, 6). The modification of process parameters—such
as solvent type, volume (7, 8), or co-encapsulation with various excipients
such as poly(ethylene glycol) (9), sugars (10), or bases (11)—can improve
encapsulation efficiency and protein stability, yet, the requirement for en-
capsulation to achieve sustained release remains unchanged.
Embedding PLGA nanoparticles (PLGA np) within a hydrogel
enables their localization at the site of hydrogel injection (12, 13),
and is known to reduce the initial burst and to extend the release of
encapsulated proteins (10, 14). While studying the release of three
growth factors relevant to central nervous system (CNS) repair strate-
gies [stromal cell–derived factor 1a (SDF1a; hereafter referred to assimply SDF), neurotrophin-3 (NT-3), and brain-derived neurotrophic
factor (BDNF)], we found that their release profiles were independent
of encapsulation. Sustained, burst-free release profiles were obtained
whether the proteins were encapsulated in PLGA np that were then
dispersed within a hydrogel (Fig. 1A) or simply mixed into the iden-
tical hydrogel with blank PLGA np (Fig. 1B). To the best of our
knowledge, this is the first study of PLGA np being used for long-term
controlled release without encapsulation. We hypothesize that adsorp-
tion due to short-range electrostatic interactions between the proteins
and the PLGA np is the governing factor for release in this system,
and we tested this hypothesis by controlling the release through nano-
particle concentration, nanoparticle size, and pH. To substantiate the
data, we performed Monte Carlo simulations based on our release
mechanism hypothesis and obtained similar release profiles.
RESULTS
Sustained release without encapsulation
We tested the release of three proteins from two hydrogels with and
without embedded PLGA np: SDF from a click cross-linked methyl-
cellulose (XMC) hydrogel (15) (Fig. 2A), and NT-3 (Fig. 2B) and
BDNF (Fig. 2C) from a physical blend of hyaluronan and methylcel-
lulose (HAMC) (16). The diffusional release of SDF, NT-3, and BDNF
from the hydrogel alone is rapid, generally reaching completion by
day 2. By encapsulating the proteins in PLGA np before mixing them
into the hydrogel (composite XMC and composite HAMC), we
achieved sustained release for at least 28 days with no burst; however,
we observed a 4- to 7-day delay in the release. Encapsulation efficien-
cies in PLGA np of 49 ± 4%, 47 ± 2%, and 47 ± 7% were achieved for
SDF, NT-3, and BDNF, respectively.
In an effort to overcome this delay, we mixed additional proteins
directly into the hydrogel with the protein-loaded PLGA np. We1 of 10
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 anticipated an initial burst release followed by a sustained release, re-
flecting fast diffusion from the hydrogel and slower diffusion from the
nanoparticles. Instead, we observed an identical release profile, with
only the total amount of released proteins increased (fig. S1) (17).
We also observed a similar release profile when all of the proteins were
simply mixed into the hydrogel with blank PLGA np (Fig. 2, A to C).
All proteins remained bioactive when released using this encapsulation-
free method (fig. S2), with all of the proteins incorporated into the
system being available for release. This overcomes the <50% efficiency
obtained with PLGA np encapsulation.
Adsorption governed by electrostatic interactions
To understand the release mechanism, we examined the physical
characteristics of this encapsulation-free release system. Nanoparticle
morphology and size were characterized by transmission electron mi-
croscopy (TEM) and dynamic light scattering (DLS). Nanoparticles
were spherical, with some visible surface morphology, an average di-
ameter of 293 ± 19 nm, and a polydispersity index of 0.21 ± 0.02 by
DLS (fig. S3). z potential measurements showed that the surface of the
PLGA np was negatively charged (−14.0 ± 0.7 mV), in agreement with
previous reports (18, 19). The swelling ratio of HAMC was compared to
that of composite HAMC (that is, PLGA np dispersed in HAMC).
Composite HAMC had a significantly higher swelling ratio after 3 days
compared to HAMC alone (fig. S4).Fig. 1. Two different PLGA np systems are compared for controlled
protein release. (A) Protein encapsulated in PLGA np dispersed in a
hydrogel. (B) Protein and blank PLGA np dispersed in a hydrogel. For
the latter, protein adsorbs to the PLGA np but is not encapsulated with-
in them. o
n
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ag.org/Fig. 2. Controlled sustained release of positively charged proteins from PLGA np does not require encapsulation. (A to C) Three different
proteins show nearly identical release profiles whether encapsulated within PLGA np or simply mixed with blank PLGA np in a hydrogel: (A) SDF (pI 10.9,
molecular mass of 8 kD, 200 ng/release), (B) NT-3 (pI 9.5, molecular mass of 27 kD, 1000 ng/release), and (C) BDNF (pI 10.9, molecular mass of 27 kD, 300 ng/release).
The cumulative percentage released is significantly greater for soluble proteins with no PLGA np compared to soluble proteins with blank PLGA np or proteins
encapsulated in PLGA np at all time points (P < 0.05, n = 3 for all releases, mean ± SD plotted). Asterisks indicate significant differences between release
of soluble protein with PLGA np and release of protein encapsulated in PLGA np (*P < 0.05, **P < 0.01, ***P < 0.001). Curves for soluble SDF with no
PLGA np and SDF encapsulated in PLGA np were taken with permission (15). (D) EPO (pI ~4, molecular mass of 30 kD, 84 ng/release) shows no
attenuated release when mixed into HAMC with PLGA np versus just HAMC alone (without PLGA np), indicating that the phenomena observed with
SDF, NT-3, and BDNF are based on short-range electrostatic interactions between positively charged proteins and negatively charged PLGA (n = 3,
mean ± SD plotted).2 of 10
R E S EARCH ART I C L E
http://adva
D
ow
nloaded from
 SDF, NT-3, and BDNF all have a net positive charge at physiolog-
ical pH, with an isoelectric point (pI) of 10.9 for SDF, 9.5 for NT-3,
and 10.1 for BDNF (20). We postulated that the delayed release that
we observed was primarily caused by adsorption due to short-range
electrostatic interactions between the protein and the PLGA np. To
test this hypothesis, we examined the release of erythropoietin
(EPO)—another protein that has shown benefits for CNS repair strat-
egies (21) and has a pI of 3.3 to 4.3 (22), making it negatively charged
at physiological pH. Soluble EPO was released just as rapidly from
composite HAMC as from HAMC alone, with complete release ob-
served after 2 days (Fig. 2D). This is consistent with our hypothesis
that adsorption is mediated by electrostatic interactions.
The hydrogel itself seems to have a minimal role in controlling re-
lease because the release of SDF from XMC and that of NT-3 and BDNF
from HAMC show similar profiles. We examined this further by re-
placing both XMC and HAMC with another common gel, agarose.
Release of soluble BDNF from agarose alone was the same as that from
HAMC alone, whereas release of soluble BDNF from agarose containing
PLGA np exhibited the same delayed-release profile that we observed
with HAMC containing PLGA np (Fig. 3A). Incubation of BDNF with
free PLGA np in artificial cerebrospinal fluid (aCSF) at the same protein/
PLGA ratio as in the hydrogels resulted in almost complete adsorption
within minutes (Fig. 3B), suggesting that the mechanism for con-
trolled release is mediated by the nanoparticles, not the hydrogel.
Adsorption mediated by electrostatic interactions can be dis-
rupted by raising the level of competing ions in solution. WhenPakulska et al. Sci. Adv. 2016; 2 : e1600519 27 May 2016the salt concentration of the release media was raised from 149 mM
(physiologically relevant) to 0.5 M, the release of BDNF from the agar-
ose PLGA np composite was fast and almost identical to the release
profile observed in the absence of the nanoparticles (Fig. 3C).
Tuning release by controlling the surface area of PLGA np
To further investigate the role of PLGA np in controlling release, we
examined the role of PLGA np surface area because the amount of pro-
tein adsorbed is proportional to the available surface area. We investi-
gated the release of BDNF from composite HAMC containing either
300-nm- or 1000-nm-diameter nanoparticles. Assuming similar densities
and spherical nanoparticles, the 1000-nm nanoparticles would have
three times less available surface area than the 300-nm nanoparticles
for the same mass (see calculations in the Supplementary Materials). Con-
sistent with our hypothesis that the interaction between PLGA np and
positively charged proteins controls release, the larger nanoparticles
(with the overall lower surface area) resulted in faster release (Fig. 4A).
The available PLGA np surface area can similarly be controlled
by the concentration of nanoparticles within the gel. We observed a
direct correlation between the number of PLGA np dispersed in the
hydrogel and the release rate of NT-3 from composite HAMC. With
the lowest concentration of nanoparticles (0.1 wt %; Fig. 4B, i), there
was a faster initial release rate that approached the diffusion-controlled
release profile of NT-3 from HAMC alone (0 wt %; Fig. 4B, i). As the
concentration of nanoparticles increased, the release rate slowed. We
were able to increase the concentration of NT-3 by 20-fold (from 0.5 o
n
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ag.org/Fig. 3. Sustained release of BDNF from agarose containing PLGA np is disrupted by increased salt. (A) BDNF shows the same delayed- and
sustained-release profile from agarose containing PLGA np as from HAMC with PLGA np while diffusional release from agarose alone is still fast.
(B) Almost all soluble BDNF is adsorbed to PLGA np after incubation, even at short times. (C) NaCl (0.5 M) completely disrupts the interaction of BDNF with
PLGA np, resulting in purely diffusional release (P > 0.05 for all time points, n = 3 for all releases, mean ± SD plotted).3 of 10
R E S EARCH ART I C L Eto 10 mg) in the 10 wt % PLGA np composite while maintaining a vir-
tually identical release profile (Fig. 4B, ii). Thus, we have a facile meth-
od to control both the release rate and the amount of protein released.
Tuning release by modifying adsorption affinity
Because adsorption can be controlled by modifying the interaction
strength between the proteins and the PLGA np, we next examinedPakulska et al. Sci. Adv. 2016; 2 : e1600519 27 May 2016the role of supernatant pH in protein release from our drug delivery
system (DDS), as supernatant pH would affect both the charge of the
protein and that of the PLGA np surface. SDF was released from
composite XMC into media at pH 3, 5, and 7. The release rate of
SDF from composite XMC (that is, in the presence of nanoparticles)
significantly increased with decreasing pH (Fig. 5A); yet, in the ab-
sence of nanoparticles, the release rate of SDF was unaffected by o
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 Fig. 4. Release of positively charged proteins from composite HAMC can be tuned by changing the available nanoparticle surface area.
(A) Cumulative percentage release of BDNF from composite HAMC is higher with 1000-nm-diameter PLGA np than with 300-nm-diameter PLGA np
while keeping PLGA np mass constant. (B) (i) Release of NT-3 from composite HAMC with 0, 0.1, 0.5, 1, and 10 wt % PLGA np. Cumulative percentage of
NT-3 released is significantly lower for 10 wt % PLGA np than for all other curves at t > 1 day (P < 0.05). Cumulative percentage of NT-3 released is
significantly higher with 0 wt % PLGA np than with 0.1 wt % (t = 1 day, P < 0.05), 0.5 wt % (1 day ≤ t ≤ 3 days, P < 0.05), and 1 wt % (t > 3 hours, P <
0.05). (ii) Release of 0.5, 1, or 10 mg of NT-3 from composite HAMC with 10 wt % PLGA np. The concentration of NT-3 incorporated can be increased up to
20 times with virtually no change in release profile. Cumulative percentage of NT-3 released is significantly higher for 10 mg than for 1 and 0.5 mg at 10 and
14 days (P < 0.05) and is significantly lower for 0.5 mg than for 1 and 10 mg at 21 and 28 days (P < 0.05) (n = 3 for all releases, mean ± SD plotted)., 2016Fig. 5. Release of positively charged proteins can be tuned by changing the environmental pH. (A) Release of SDF from composite XMC into media
at pH 3, pH 5, or pH 7. Cumulative percentage release of SDF is significantly greater at pH 3 than at pH 5 (t < 10 days, P < 0.01) and pH 7 (t > 0 days, P < 0.0001),
likely because PLGA carboxylate anions are protonated to carboxylic acids, thereby reducing electrostatic interactions with positively charged proteins.
(B) Release of BDNF from HAMC with PLGA np with or without encapsulated magnesium carbonate (MgCO3). Release is delayed with encapsulated MgCO3 (a
basic salt), which neutralizes acidic degradation products and thereby maintains a higher/neutral local pH (n = 3 for all releases, mean ± SD plotted).4 of 10
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 decreasing pH (fig. S5). Moreover, the difference in release cannot
be explained by destabilization of the gel at lower pH, because there
was no significant mass loss of PLGA from the hydrogel over the
first 7 days of release at either pH 3 or pH 7 (fig. S6). Thus, these
data indicate that pH can be used to control release and that, at lower
pH (where the carboxylate anions of PLGA are protonated), the
electrostatic interaction between PLGA anions and protein cations
is diminished.
To investigate the effects of local pH on protein release, we com-
pared the release of BDNF from composite HAMC containing
PLGA np with and without encapsulated MgCO3. Because PLGA
is known to degrade into acidic products by bulk degradation, the
encapsulation of basic salts has been used to delay pH changes with-
in PLGA np (11). Release of soluble BDNF from composite HAMC
had a delay of approximately 7 to 10 days with encapsulated MgCO3
(Fig. 5B). In contrast, in the absence of MgCO3, the delay was
shortened to just 4 days. This suggests that the mechanism for pro-
tein release is related to a change in PLGA charge from negative car-
boxylate anions to neutral carboxylic acids, which is slowed in the
presence of MgCO3.
Monte Carlo simulations
As a further test of our hypothesis for release mechanism, we per-
formed three-dimensional on-lattice Monte Carlo simulations of pro-
tein release from a hydrogel with a stochastic logistic-population
model for the degradation of the PLGA np. The nanoparticles were
modeled as cubic obstacles having short-range interactions with the
proteins. We included both a deep attractive potential well to model
electrostatic adsorption and a low repulsive barrier to adsorption, with
both potentials approaching zero as the nanoparticles degrade. This
scheme is observable qualitatively in heuristic two-dimensional sim-
ulations (see movie S1). We used this model to reproduce the releasePakulska et al. Sci. Adv. 2016; 2 : e1600519 27 May 2016curves obtained in Fig. 4B(i) by fitting the simulation parameters to
best match the case of 10 wt % PLGA np, then using those same param-
eters for all other simulations without any additional fitting (Fig. 6).
The combined reduced c2 value for all simulations was 3.9.
Although the simulation parameters were chosen to best repro-
duce the 10 wt % curve with its clear plateau region and secondary
rise, the 0, 0.1, and 0.5 wt % curves are also well described.
Intermediate concentrations, such as 1 wt %, show the least agree-
ment, demonstrating the implicit effects of a finite gel size on the
relative significance of protein-nanoparticle interactions and diffu-
sion in Monte Carlo simulations.DISCUSSION
Models of drug release from PLGA np usually consider polymer deg-
radation, erosion, and diffusion of the drugs through the resulting
water-filled pores as rate-determining (1, 23). However, our results
show very similar release profiles for three different proteins whether
they are encapsulated in PLGA np or simply mixed with them, in-
dicating that another mechanism must be involved.
We postulate that initially the protein is fully adsorbed to the neg-
atively charged nanoparticle surface (Fig. 7, i). As the nanoparticle
begins to degrade, acidic components build up and decrease the local
pH (Fig. 7, ii). At a certain threshold, the original negative carboxylate
anion on the nanoparticle surface becomes protonated to carboxylic
acid, thereby weakening the electrostatic interactions with the positive-
ly charged proteins and initiating release (Fig. 7, iii). Release can then
be governed by nanoparticle degradation and protein diffusion and/or
adsorption/desorption, depending on the system. o
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ag.org/Fig. 6. Monte Carlo simulations agree well with experimental
results. Release of NT-3 from HAMC with 10 wt % PLGA np (Fig. 4B, i)
was fitted using three-dimensional on-lattice Monte Carlo simulations.
Simulations were then run for all other nanoparticle concentrations in
Fig. 4B(i) using the same parameters. The combined reduced c2 value
for all simulations was 3.9. Symbols represent data, whereas solid lines
represent the simulation results.Fig. 7. Adsorption may be rate-limiting for the release of positively
charged proteins from PLGA np. (i) Initially, the protein is fully ad-
sorbed to the negatively charged nanoparticle surface. (ii) As the nano-
particle begins to degrade, acidic components build up and decrease
the local pH. (iii) At a certain threshold, the nanoparticle surface
becomes neutral, weakening the electrostatic interactions with the pos-
itively charged proteins and initiating release.5 of 10
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 It is possible that the presence of the PLGA np affects the release of
proteins simply by changing the gel mechanics. Methylcellulose forms
a gel via hydrophobic interactions, and its shear modulus increases
upon incorporation of PLGA np, suggesting additional hydrophobic
interactions between methylcellulose and PLGA np (12). These hydro-
phobic interactions have been postulated to affect the release rate of
proteins from PLGA np (10). However, our results show that the ad-
dition of PLGA np actually increases the hydrogel swelling ratio, likely
as a result of the presence of carboxylate anions on the PLGA np sur-
face. Increased swelling of poly(acrylic acid) gels with the addition of
polystyrene nanoparticles has been attributed to the sulfonic acid
groups on the nanoparticle surface (24), and carboxylate anions have
previously been found to affect the swelling of hydrogels. Increased
swelling should lead to an increased mesh size and subsequently
increased release rate of a protein (25); however, our data show the
opposite effect, indicating an interaction between PLGA np and the
protein. In addition, changes in mesh size would be expected to affect
all proteins, depending on their size; however, EPO, which has a molar
mass larger than that of SDF and similar to those of NT-3 and BDNF,
does not show sustained release in the presence of PLGA np. Thus, gel
mechanics are unlikely the mechanism controlling the release of pro-
teins from composite PLGA np hydrogels.
Adsorption is recognized as one of the factors affecting the re-
lease of biomolecules encapsulated in PLGA particles (26) and is a
major cause of incomplete release (27, 28). Adsorption of proteins
at the surface of PLGA particles is also often cited as the cause of
the initial burst observed in the release from PLGA np formula-
tions (29) and is attributed to a combination of electrostatic and
hydrophobic interactions (18, 30). The release of proteins adsorbed
to the surface of PLGA particles is often fast (within the first 1 to
8 hours of release) and has not been fully studied (18, 31).
To examine the possibility of a hydrogel effect, we tested release
from agarose, an uncharged polymer with a mechanism of gelation
(32) different from that of either XMC (15) or HAMC (16, 33). The
release profiles of BDNF were the same whether from composite
HAMC or composite agarose, suggesting a specific interaction be-
tween the protein and the PLGA np, not the hydrogel. When we
incubated BDNF with PLGA np alone at the same ratio used in
the release studies, almost all the BDNF was removed from the su-
pernatant within minutes, demonstrating a strong interaction with
the PLGA np.
Adsorption is governed by noncovalent interactions, including
electrostatic, hydrophobic, and van der Waals forces. Given that
SDF, NT-3, and BDNF are all positively charged at neutral pH, and
a negatively charged protein (EPO) did not show the same release be-
havior, we hypothesized that electrostatic interactions were governing
protein adsorption. The range of electrostatic interactions is governed
by the Debye length. For our release system, the Debye length is very
small (<1 nm), so long-range electrostatic interactions are not impor-
tant; however, short-range interactions likely still exist. Electrostatic
interactions such as these can be disrupted with an excess of ions.
In fact, BDNF is often purified using ion exchange chromatography,
and a salt concentration of 0.5 M is within the range used for elution
(34, 35). When we examined the release of BDNF from composite
agarose in the presence of 0.5 M NaCl, the release rate approached
diffusional values. This supports a hypothesis of predominantly
electrostatically controlled adsorption to the PLGA np, with little con-
tribution from hydrophobic and van der Waals forces (36).Pakulska et al. Sci. Adv. 2016; 2 : e1600519 27 May 2016Control over the release rate is essential for the success of sustained
delivery formulations. We explored different parameters of our DDS
and their effects on the release rate of soluble proteins. Models of drug
release controlled by adsorption/desorption demonstrate that release is
governed by the number of available binding sites and the strength of
the interaction (18, 37).
Nanoparticle size can be readily varied by modifying the formula-
tion conditions (4) and is therefore a facile method to control release.
Assuming a similar density, smaller nanoparticles provide an overall
larger surface area and would therefore increase the extent of adsorp-
tion. We show that BDNF released from HAMC with 300-nm nano-
particles showed a longer delay and slower release than that from
HAMC with 1000-nm nanoparticles.
Because protein loading and nanoparticle concentration are de-
coupled in our DDS, changing the nanoparticle concentration pro-
vides a simple method to tune release. In general, release of NT-3 is
faster with lower nanoparticle concentrations. When the nanopar-
ticle concentration is decreased from 10 to 1 wt % with a constant
amount of protein, a significant burst release is seen. On the other
hand, increasing the protein concentration 10-fold while maintain-
ing the nanoparticle concentration at 10 wt % does not change the
release profile of NT-3 despite an identical nanoparticle/protein
mass ratio as the 1 wt % case above. A similar effect is seen in
affinity-controlled release systems: as long as the available binding
sites are in excess, the release rate depends on the concentration
of binding ligand (here the PLGA np), not on the binding ligand/
protein ratio (38).
Theoretically, complete surface coverage of our PLGA np occurs
at 1.41 wt % protein loading (see calculations in the Supplementary
Materials). When increasing protein concentration, we never ex-
ceeded 0.1 wt % protein loading by mass because of the significant
costs of these proteins; however, on the basis of our calculations, we
expect that a 1–wt % loading could be achieved without significant-
ly altering the release profile. This suggests that our DDS could
deliver substantially higher loadings than previously reported for
PLGA encapsulation of therapeutic proteins such as NT-3 (39),
BDNF (40–42), or nerve growth factor (43, 44).
PLGA np lose their negative charge at or below pH 5 (19), thus
decreasing their charge attraction to positively charged proteins.
We observed increased release rates of SDF at pH 3 and 5 com-
pared to pH 7. This is not attributable to gel destabilization at
low pH because there is no significant mass loss of PLGA np over
7 days at pH 3 or pH 7. The ability to increase the release rate at
acidic pH may have interesting implications for in vivo delivery at
acidic sites, such as the tumor microenvironment (45).
In all of the release profiles, a constant, slow release phase was
observed after the initial delay or burst. PLGA degrades by bulk
degradation into acidic components, which are often trapped with-
in the nanoparticles before their dissolution, decreasing the pH
inside the nanoparticles (11, 28). We postulate that this reduction
in local pH reduces the magnitude of the protein-polymer interac-
tion (as shown in our pH study) and initiates protein release as a
certain pH threshold is reached. Thus, by controlling the pH
change within the PLGA np, it should be possible to eliminate or
extend this delay. Indeed, encapsulation of a basic salt, MgCO3, slowed
the release of BDNF from PLGA np dispersed in HAMC, likely by
decreasing the rate of PLGA degradation and pH change within the
nanoparticles. Similarly, PLGA polymers with different properties6 of 10
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 (molecular weight, end group, and lactide/glycolide ratio) could also
be used to formulate nanoparticles with various degradation rates to
achieve different release profiles.
Agreement between the minimal Monte Carlo simulations and the
experimental data further suggests that the release curves result from
(i) an initial diffusive regime during which proteins either escape the
hydrogel or adsorb to a nanoparticle, (ii) a plateau region, and, finally,
(iii) a secondary rise attributable to the release of the proteins follow-
ing PLGA np degradation. The model overpredicts the initial burst for
lower nanoparticle concentrations, especially the 1 wt % case, which is
likely a result of the small finite size of the simulated system. The
model also predicts an eventual rise (phase 3) for lower nanoparticle
concentrations that we expected but did not observe experimentally.
It is possible that the releases were simply not taken to long-enough
time points to observe this phase, or perhaps a portion of the protein
was adsorbing irreversibly at longer time points when the pH changes
were not as rapid. However, reproducing the general shape of the re-
lease curves and obtaining adequate agreement for five different release
curves using a single set of parameters show that the release hypothesis
is robust.
Although we cannot rule out the possibility that the polymer
degradation, irrespective of the pH change, decreases the affinity
of the protein for the nanoparticles, previous studies have shown
that the available surface area for adsorption actually increases as
the nanoparticles degrade, which would likely result in increased
adsorption and slower release (27). Therefore, it seems more likely
that polymer degradation indirectly affects protein release through
pH change.
Using PLGA for the release of bioactive proteins without en-
capsulation is a paradigm shift in controlled delivery, and the use of
the well-established PLGA facilitates clinical translation. Furthermore,
controlled release is obtained without any modifications to the protein
that may affect activity. Tunable release is achieved by varying simple
formulation parameters, and stimuli-responsive release is demon-
strated by modifying environmental pH. The next step is the extension
of these concepts to additional proteins. Although we show similar
release profiles for three different proteins, not all proteins can be
expected to interact in the same way. A simple adsorption experiment
could quickly ascertain whether this method is suitable for a given
protein. Polymer composition (for example, end group and lactide/
glycolide ratio) might also be tailored to suit a particular protein. Al-
though not explored herein, for controlled release of negatively
charged proteins, PLGA np could be coated with positively charged
polymers, such as chitosan (46), or positively charged polymeric nano-
particles that degrade into basic components could be used instead.
The results presented here provide the basis for a fundamental change
in the way we use PLGA for protein delivery.MATERIALS AND METHODS
PLGA was purchased from Sigma-Aldrich (50:50 lactide/glycolide,
carboxy-terminated, molecular mass of 7 to 17 kD), and LACTEL Ab-
sorbable Polymers were purchased from Durect Corp. (50:50 lactide/
glycolide, carboxy-terminated, 0.15 to 0.25 dl/g in hexafluoroisopro-
panol). Proteins were sourced as follows: SDF (R&D Systems), NT-3
(PeproTech), BDNF (PeproTech), and EPO (Janssen). Enzyme-linked
immunosorbent assay (ELISA) kits for SDF and NT-3 were purchasedPakulska et al. Sci. Adv. 2016; 2 : e1600519 27 May 2016from R&D Systems, and those for BDNF were purchased from Pro-
mega. All other materials were obtained as indicated.
PLGA np formation
PLGA np were formed by water/oil/water double-emulsion solvent
evaporation, as previously described by Baumann et al. (47). Briefly,
120 mg of PLGA and 0.05% Pluronic NF-127 (BASF) were dissolved
in 900 ml of dichloromethane (DCM; Caledon Laboratories) and vor-
texed with 100 ml of bovine serum albumin (BSA; 120 mg/ml; Sigma
Aldrich) in aCSF [149 mMNaCl, 3 mM KCl, 0.8 mMMgCl2, 1.4 mM
CaCl2, 1.5 mM Na2HPO4, and 0.2 mMNaH2PO4 (pH 7.4)] to achieve
10% w/w BSA/PLGA in the final formulation. The mixture was then
sonicated for 2 min on ice. For encapsulation of SDF, NT-3, BDNF, or
EPO, these proteins were dissolved in the aqueous phase before son-
ication. The primary emulsion was then added to 3 ml of a 2.5% (w/v)
**solution of poly(vinyl alcohol) (30 to 70 kg/mol; Sigma Aldrich),
vortexed, and sonicated for 2 min on ice. This secondary emulsion
was added to a hardening bath of poly(vinyl alcohol) (PVA) and stirred
for a minimum of 4 hours to allow the DCM to evaporate. The result-
ant nanoparticles were washed four times by ultracentrifugation, lyophi-
lized, and stored at −20°C. Nanoparticles were sized by DLS (Malvern
Instruments). For 1000-nm nanoparticles, the volume of PVA added in
the secondary emulsion was increased to 5 ml.
Measurement of encapsulation efficiency
Stromal cell–derived factor 1a. Encapsulation efficiency was
measured by dissolving 10 mg of dry protein-loaded PLGA np in
1 ml of dimethyl sulfoxide for 1 hour at 37°C. Ten milliliters of
0.05 M NaOH containing 0.5% (w/v) sodium dodecyl sulfate was then
added, and the sample was left for another hour at room temperature
on a rocker. SDF concentration was then measured by ELISA at a 1:10
dilution as directed.
BDNF/NT-3. Encapsulation efficiency was measured by dissolv-
ing 5 mg of dry protein-loaded PLGA np in 5 ml of 0.05 M NaOH
on a shaker at room temperature for 30 min. The protein concen-
tration was determined by ELISA.
Preparation of PLGA np/hydrogel DDS
Composite HAMC. To form the HAMC hydrogel, we dissolved
methylcellulose (300 kg/mol; Shin-Etsu) and sodium hyaluronate
(HA; 1.4 to 1.8 × 106 g/mol; NovaMatrix) in aCSF, using a dual
asymmetric centrifugal mixer (FlackTek), to a final concentration of
2.8% (w/v) HA and 6% (w/v) methylcellulose. Nanoparticles were dis-
persed in aCSF at 20% (w/w) by 5 min of bath sonication, and protein
(NT-3, BDNF, or EPO) was then added. Composite HAMC was
formed by blending the nanoparticle dispersion and HAMC at a 1:1
ratio using a dual asymmetric centrifugal mixer.
Composite XMC. XMC was prepared as previously described
(15), except that empty PLGA np dispersed in aCSF and SDF were
added before mixing in the cross-linker.
Composite agarose. Ultralow gelling temperature SeaPrep Agar-
ose (Lonza) was dissolved in aCSF to a concentration of 3% (w/v) by
microwaving on high power in 4-s bursts and vortexing until clear.
The solution was allowed to cool to room temperature before further
handling. Nanoparticles were dispersed in aCSF at 20% (w/w) by
5 min of bath sonication, and BDNF was then added. Room tempe-
rature agarose was added to the nanoparticle dispersion at a 1:1 vol-
ume ratio, and a dual asymmetric centrifugal mixer was used to create7 of 10
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 the composite agarose. One hundred microliters of composite agarose
was pipetted into a 2-ml centrifuge tube and allowed to gel at 4°C for
1 hour.
In vitro release assays
Composite HAMC/XMC. One hundred microliters of either
HAMC, XMC, composite HAMC, or composite XMC, with or with-
out dispersed protein, was injected into a 2-ml centrifuge tube. After
10 min of gelation at 37°C, 900 ml (for release of BDNF and NT-3) or
400 ml (for release of SDF) of prewarmed aCSF was added. For BDNF
releases, the aCSF also contained 0.1% (w/v) BSA to ensure sustained
bioactivity. The supernatant was completely replaced at designated
time points for the duration of the release study, and the protein con-
centration was assessed by the relevant ELISA. At the conclusion of
the study, the remaining gel was processed as described above for en-
capsulation efficiency, and the remaining protein was quantified by
ELISA. Releases were performed in triplicate. For release of SDF at
different pH values, the pH of the aCSF was adjusted to pH 5 or
pH 3 and used in both the gel formation and the supernatant.
Agarose/agarose with high salt. Agarose or agarose composite
with or without dispersed BDNF, previously prepared in a 2-ml cen-
trifuge tube, was placed in an incubator at 37°C to warm for 10 min.
Nine hundred microliters of prewarmed aCSF (0.1% w/v BSA) was
added to the composite, and this supernatant was completely re-
placed at designated time points for the duration of the release study.
For the high-salt agarose composite, aCSF with 0.5 M NaCl was used
to create the gel and the release supernatant. At the end of the study,
0.5 ml of 0.5 M NaCl was added to the gel to release any remaining
BDNF. ELISA was used to determine BDNF concentration at each
time point and the BDNF remaining in the gel. Releases were per-
formed in triplicate.
Adsorption study
Two micrograms of BDNF was mixed with 20 mg of PLGA np in 200 ml
of aCSF and incubated for 0 min (as fast as possible), 10 min, and 60 min
at 37°C. At each designated time point, the mixture was centrifuged at
12,000 rpm for 2 min to pellet the nanoparticles. The supernatant was
carefully removed and analyzed by ELISA. Controls of soluble BDNF in
aCSF with no nanoparticles were processed in the same way at each time
point to take into account any losses resulting from centrifugation or ad-
sorption to the tube. Samples of PLGA np in aCSF with no BDNF were
used as blanks for the ELISA. The amount of BDNF adsorbed to the
nanoparticles was calculated as 2 mg minus the amount detected in the
supernatant. Each time point was performed in triplicate.
Bioactivity assays
All animal procedures were performed in accordance with the Guide
to the Care and Use of Experimental Animals (Canadian Council on
Animal Care), and protocols were approved by the Animal Care
Committee at the University of Toronto.
NT-3: Dorsal root ganglia explant assay. The bioactivity of re-
leased NT-3 was quantified as previously described by Stanwick et al.
(10). Sprague-Dawley rat embryo dorsal root ganglia (DRG; E17) were
harvested and pooled in neural basal media containing 1 volume % fetal
bovine serum, 2 volume % B-27 serum-free supplement, 1 volume %
penicillin-streptomycin, and 1 volume % L-glutamine. The DRG
were placed on glass coverslips (12 mm in diameter) coated with
poly-D-lysine (50 mg/ml in sterile water) and laminin (5 mg/ml inPakulska et al. Sci. Adv. 2016; 2 : e1600519 27 May 2016phosphate-buffered saline) in a 24-well plate. Media with aCSF
alone (control media), media with soluble (standard) NT-3, or
media with released NT-3 were added to each well. The DRG were
fixed after a 48-hour incubation in 4% paraformaldehyde and
stained with NF200 and 4′,6-diamidino-2-phenylindole (DAPI;
Sigma Aldrich). DRG were imaged on an Olympus FV1000 con-
focal microscope. Image analysis was performed with ImageJ (Na-
tional Institutes of Health). For each DRG, the DAPI-positive area
of the multicellular DRG body was subtracted from the total
NF200-positive area (center + extended neurites) to yield the area
of neurite outgrowth. A minimum of three DRGs were assayed per
group.
SDF: Neurosphere migration assay. In vitro activity of SDF
was quantified as previously described (15). Briefly, 125 ml of SDF re-
lease samples or controls was diluted to 2000 ng/ml (or as high as
possible) in serum-free media and adjusted to pH 7. Each was then
added to 125 ml of adult rat spinal cord neurosphere suspension in a
fibronectin-coated 48-well tissue culture plate. Neurospheres were
allowed to adhere for 1 hour in a tissue culture incubator at 37°C
and 5% CO2. Images of four neurospheres per well were collected
using an inverted Olympus laser scanning confocal microscope with
automated stage at ×10 magnification. The coordinates of each image
were saved. The plate was then returned to the incubator. Using the
saved coordinates, we again imaged the same neurospheres 24 hours
later. Images were analyzed using ImageJ (National Institutes of
Health). The initial area of the neurosphere (A1) and the final area
of cells migrated out from the neurosphere (A2) were measured
and subtracted to yield the total area of migration (A2 − A1).
BDNF: DRG neurite outgrowth assay. In vitro activity of BDNF
was determined using a DRG bioassay. Rat embryo DRG (E17 female
Sprague-Dawley rats, n = 3) were removed and pooled in media com-
posed of neural basal media supplemented with 2% B-27 serum-free
supplement, 1% penicillin-streptomycin, and 1% L-glutamine (Life
Technologies). The DRG were then placed on 12-mm-diameter glass
coverslips coated with poly-D-lysine (50 mg/ml) and laminin (5 mg/ml)
in a 24-well plate. Each release sample replicate was tested on a
separate plate. All wells contained three DRG and were treated with
0.5 ml of media and 0.5 ml of the BDNF release study supernatant
(7, 28, 35, and 42 days). For the controls, 0.5 ml of media and 0.5 ml
of aCSF (without BDNF) were added to the wells. The DRG were
grown for 48 hours at 37°C and 5% CO2, fixed with 4% para-
formaldehyde, and processed for immunocytochemistry. The DRG
were imaged using an inverted confocal laser scanning microscope
(Olympus FV1000). Neurite outgrowth area was calculated by sub-
tracting the cell body area from the total area of the DRG neurite
outgrowth. To account for any differences in cell body size, we stan-
dardized the neurite outgrowth area to the cell body area for statis-
tical analysis. Neurite outgrowth of DRG treated with release
samples was compared to controls to assess bioactivity.
Transmission electron microscopy
PLGA np were suspended in water at 2 mg/ml with sonication for
5 min. A sample (5 ml) was deposited onto a freshly glow-discharged
400-mesh carbon-coated copper TEM grid (Ted Pella Inc.) and
allowed to adhere for 4 min. Excess liquid was removed with filter
paper, and nanoparticles were then stained with 2% uranyl acetate
(UA, w/v, 5 mL, pH 4.3, 15 seconds). Stain was wicked away with filter
paper, and samples were immediately imaged using a Hitachi H-70008 of 10
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 microscope operating at 75 kV. Images were captured using an Advanced
Microscopy Techniques XR-60 CCD camera with typical magnifica-
tions between ×30,000 and ×75,000.
z potential measurements
PLGA np were suspended at 0.1 mg/ml in distilled water with
1 mM KCl. z potential was measured in a disposable folded capil-
lary cell using a Zetasizer Nano ZS (Malvern Instruments).
Swelling study
An in vitro swelling study was performed as previously described (15).
Briefly, 180 ml of HAMC or composite HAMC was injected into a
2-ml centrifuge tube. After incubation at 37°C for 10 min, 1620 ml
of prewarmed aCSF was added. At each time point, the tube was
weighed after complete removal of the aCSF. The normalized
swelling ratio, Q, was determined by the equation
Qt ¼ mt mtubem0 mtube
where mt is the total mass at each time point, m0 is the total mass at
time 0, and mtube is the mass of the centrifuge tube.
Monte Carlo modeling
The on-lattice Monte Carlo simulations model proteins as nonin-
teracting point particles stochastically diffusing on a three-dimensional
cubic lattice of size a, representing the hydrogel, with an effective
diffusion coefficient (48). Proteins that diffuse to the edge of the
cubic simulation box permanently escape the hydrogel. For deter-
mination of the Monte Carlo time step, tMC (in hours), for a set of
simulations of a hydrogel of size L, a simulation is run in the ab-
sence of PLGA np, and the rapid diffusional release rate is matched
to the experimental cumulative release. For L = 100a, the conver-
sion (0.0148 ± 0.0001) hours/tMC is found. To simulate embedded
PLGA np, we introduce a number of impenetrable obstacle lattice
sites that exclude proteins. Each randomly placed, nonoverlapping
nanoparticle (labeled i) is cubic with a hard-core size 2R + a. In
addition to the hard core, each nanoparticle interacts with the pro-
teins through a double step-function potential. Immediately adja-
cent to the core is a deep attractive potential well of depth ui(t)
per thermal energy and range a. Large negative values of ui(t)
cause proteins to be tightly bound to nanoparticles. In addition,
there is a repulsive step-potential height ei(t) per thermal energy
and of range a, which represents the barrier to adhesion. Adsorp-
tion is modeled via a simple Metropolis algorithm. For a simu-
lated decrease in attraction due to PLGA hydrolysis, the potentials
approach zero after long times as uiðtÞ ¼ ½1 cNiðtÞ=Ku0 and
eiðtÞ¼½1 cNiðtÞ=Ke0, where c is the number density of nanoparticles,
K is the nanoparticle-hydrogel degradation-product carrying capacity per
hydrogel volume, and Ni(t) is the stochastically increasing number of
degradation products. The number of degradation products grows ran-
domly via an algorithm that reproduces logistic-population statistics
dNi
dt ¼ r0Ni tð Þ 1 ∑NiðtÞK L3
h i
, where the summation occurs over all nano-
particles in the hydrogel and r0 represents the first-order PLGA degra-
dation rate constant. This captures the increase in the degradation rate
due to the increase in acidic degradation products over time (self-Pakulska et al. Sci. Adv. 2016; 2 : e1600519 27 May 2016catalyzed PLGA degradation), while limiting the degradation rate by
the degradation-product carrying capacity. The free simulation param-
eters are r0, K, u0, and e0. We presume from the flatness of the plateaus
in the cumulative percentage released (Figs. 2 to 5) that |u0|≫ kBT and
thus chose the large value u0 = −10kBT. This leaves the degradation rate,
the near-unity carrying capacity, and the barrier height. These are
determined by fitting the highest concentration (10 wt %) release curve,
which has themost pronounced effects due to degradation. The param-
eters found areK = (0.350 ± 0.025)a−3, e0= (1.025 ± 0.025)kBT, and r0 =
(0.37 ± 0.02)d −1. All other simulations were run using the same param-
eters with a combined reduced c2 value of 3.9.
Statistical analysis
Statistical analysis was performed using GraphPad Prism software. For
all tests, *P < 0.05, **P < 0.01, and ***P < 0.001. Releases were ana-
lyzed using two-way analysis of variance (ANOVA), followed by the
Sidak test for multiple comparisons if there were two groups or Tukey’s
test for multiple comparisons if there were more than two groups. Ac-
tivities of NT-3, SDF, and BDNF were analyzed using one-way ANOVA
followed by Dunnett’s post hoc test comparing them to controls.SUPPLEMENTARY MATERIALS
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